The next chapter in the Valeant Pharmaceuticals Intl Inc VRX 5.36% story began today when the company named Joseph Papa as its new CEO. Shareholders are hoping that Papa can right the ship after a whirlwind of controversy has driven Valeant’s share price down 63.1 percent so far in 2016.

Papa was formerly CEO of Perrigo Company plc Ordinary Shares PRGO 0.23%, company that makes store-brand versions of over-the-counter drugs like Sudafed and NyQuil.

For Valeant shareholders wondering what they can expect from Papa, the initial market reaction to the news could be a good first indication. Valeant’s stock is up 3.7 percent in early Monday trading, while Perigo’s stock has crashed 13.2 percent on news of Papa’s departure.

Papa took over as CEO of Perigo in October of 2006. Since that time, the stock is up an incredible 595.6 percent, although it was down more than 30 percent in the past year prior to his departure.

Prior to his time at Perigo, Papa served…

Click here to continue reading

Want to learn more about how to profit off the stock market? Or maybe you just want to be able to look sophisticated in front of your coworkers when they ask you what you are reading on your Kindle, and you’d prefer to tell them “Oh, I’m just reading a book about stock market analysis,” rather than the usual “Oh, I’m just looking at pics of my ex-girlfriend on Facebook.” For these reasons and more, check out my book, Beating Wall Street with Common Sense. I don’t have a degree in finance; I have a degree in neuroscience. You don’t have to predict what stocks will do if you can predict what traders will do and be one step ahead of them. I made a 400% return in the stock market over five years using only basic principles of psychology and common sense. Beating Wall Street with Common Sense is now available on Amazon, and tradingcommonsense.com is always available on your local internet!